Mycoses. 2021 Sep 23. doi: 10.1111/myc.13373. Online ahead of print.
BACKGROUND: Isavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. It has been previously reported that an interaction between flucloxacillin and voriconazole may lead to subtherapeutic voriconazole exposure, when used concomitantly. Since isavuconazole is also metabolized via cytochrome P450 enzymes, the same interaction may be expected.
OBJECTIVES: We aim to document exposure to isavuconazole in patients concomitantly treated with flucloxacillin.
PATIENTS: We report two patients treated with both isavuconazole and flucloxacillin, in whom we determined isavuconazole concentrations.
RESULTS: Low isavuconazole trough concentrations (< 1 mg/L) were observed in two patients under concomitant treatment with flucloxacillin.
CONCLUSIONS: In combination with flucloxacillin, low isavuconazole concentrations were observed but an adequate isavuconazole exposure may be reached with dose augmentation. Therapeutic drug monitoring of isavuconazole is recommended to ensure an adequate exposure.